Department of Neurology and Critical Care, CARE Institute of Neurosciences, CARE Hospitals, Banjara Hills, Hyderabad, Telangana, India.
Department of Neurology, CARE Institute of Neurosciences, CARE Hospitals, Banjara Hills, Hyderabad, Telangana, India.
Neurol India. 2021 Nov-Dec;69(6):1772-1776. doi: 10.4103/0028-3886.333460.
This report describes a patient with thymomatous myasthenia gravis (MG) with aplastic anemia in pharmacological remission and COVID-19 who developed respiratory failure in the course of the disease and reviews the published literature on this topic. Analysis of the clinical characteristics of the eight patients with MG including our patient suggests two possible mechanisms for respiratory failure: myasthenic crisis (MC) or pulmonary complications of COVID-19. Patients with MC were young women in high-grade MGFA Class whereas patients with respiratory failure due to pulmonary complications of COVID-19 were elderly men in pharmacological remission or MGFA Class I. These observations suggest that COVID-19, like other infections, may precipitate MC in patients with severe grade MG before COVID-19. The only differentiating feature between the two types of failure was severity myasthenic weakness. This clinical distinction has management implications. These observations need to be validated in a larger sample.
本报告描述了一例伴有再生障碍性贫血的胸腺瘤性重症肌无力(MG)合并 COVID-19 的患者,该患者在疾病过程中发生呼吸衰竭,并对该主题的已发表文献进行了回顾。对包括我们的患者在内的 8 例 MG 患者的临床特征进行分析提示,呼吸衰竭可能有两种机制:肌无力危象(MC)或 COVID-19 的肺部并发症。发生 MC 的患者为重症 MGFA 分级的年轻女性,而因 COVID-19 的肺部并发症导致呼吸衰竭的患者为处于药物缓解期或 MGFA 分级 I 期的老年男性。这些观察结果表明,COVID-19 可能与其他感染一样,在 COVID-19 之前,使重症 MG 患者发生 MC。两种衰竭类型的唯一区别特征是肌无力的严重程度。这一临床区别具有管理意义。需要在更大的样本中验证这些观察结果。